NVS : Analysis & Opinions

  1. How to Analyze Pharma Stock Fundamentals

    April 23, 2015
    What you need to know about analyzing the fundamentals of pharma stocks.
  2. What are examples of major companies in the drugs sector?

    April 1, 2015
    Identify the major players in the drugs sector, which include many established pharmaceutical companies that have delved ...
  3. How is a Spinoff Worth $100 Billion? See AbbVie

    April 1, 2015
    An in depth look at Abbott Labs spinoff AbbVie and how it became a nearly $100 billion company.
  4. The Future of Big Pharma Stocks

    March 31, 2015
    A look at the future health of big pharma stocks.
  5. Interested In Pharmaceutical Stocks? Try Novartis (ADR)

    February 26, 2015
    Novartis AG, is the world's leading pharmaceutical company by sales. Here is a closer look at Novartis, and how its financials ...
  6. Use This ETF To Trade The Swiss Franc

    January 23, 2015
    Traders were stunned last week when the Swiss National Bank removed the currency peg that tied the value of the Swiss franc ...
  7. Most Powerful And Influential Public Companies In 3 Metrics

    December 9, 2014
    There are many ways to rank the word's most powerful companies. Looking at market value, brand value or sales revenue are ...
  8. How Merck Found Its Way Into Millions Of Medicine Cabinets

    September 15, 2014
    With over $40 billion in revenue from pharmaceutical sales, there's a good chance that you'll be very grateful for one of ...
  9. After A Sharp Pullback, Is Allergan Pretty Enough?

    July 31, 2013
    Down on fears about generics and the pipeline, the Street may be underestimating Allergan
  10. Taking The Contrarian Approach With European Equities

    July 2, 2013
    Investors continue to shun European equities due to the regions debt issues and economic problems. However, that’s a real ...
  11. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  12. Big Pharma Faces 'Pay For Delay' Lawsuits

    June 21, 2013
    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of ...
  13. After A Good Run, Novartis Looks Fairly Valued

    June 12, 2013
    Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.
  14. AstraZeneca Pays Up To Patch Up Another Key Area

    June 10, 2013
    In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
  15. Teva Still Too Cheap, But Still Too Uncertain

    May 3, 2013
    Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
  16. Foreign-Owned American Companies

    December 10, 2012
    Buying American, or investing in American companies, is not as easy as it once was, especially when American companies aren't ...
  17. Fiat Finally Convinces CNH To Seal The Deal

    November 26, 2012
    CNH Global agreed to merge into a new company with Fiat Industrial. Find out what this means for shareholders.
  18. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  19. Fallacy Of International ETFs

    June 26, 2012
    The expansion of the ETF industry over the last several years has been well documented; there are now more than 1,400 exchange-traded ...
  20. Eli Lilly Paying Investors To Wait

    May 3, 2012
    The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before ...
  21. Nestle Almost Never On Sale

    April 24, 2012
    Nestle has a well-earned reputation for excellence and the Street has long been happy to pay a premium for that performance. ...
  22. Atrion: A Niche Micro Cap That Will Make You Money

    January 20, 2012
    With a stock price over $200, you wouldn't think Atrium is a micro-cap.
  23. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  24. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  25. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  26. It's Time To Invest In Switzerland

    October 19, 2011
    Swiss stocks may offer a more conservative hiding place.
  27. Time To Invest In Switzerland?

    September 26, 2011
    Swiss stocks may offer a more conservative hiding place.
  28. Endo And Forest – Dumpster-Diving In Pharma

    September 21, 2011
    Endo and Forest have problems; however, the valuations seem excessively low.
  29. When Times Are Tough, Should Investors Go Swiss?

    September 15, 2011
    Swiss stocks may offer a more conservative hiding place.
  30. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  31. Going Global

    July 25, 2011
    Most investors never stray away from their home nations when it comes to portfolio construction.
  32. Top Drug Stocks

    June 30, 2011
    Recently, three strong factors are driving investors to the drug sector.
  33. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  34. Should Investors Worry If Gen-Probe Doesn't Sell Out?

    June 10, 2011
    Not selling may be the best move Gen-Probe can make for its shareholders.
  35. A Dull ASCO And The Usual Sell-Off

    June 7, 2011
    Investors shouldn't be spooked by the normal post-ASCO sell-off
  36. 6 Overbought Stocks To Watch

    May 31, 2011
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  37. Will Nestle Succeed Where Others Have Failed?

    May 26, 2011
    Nestle is making an interesting step into medical pharmaceuticals and diagnostics.
  38. Teva And Cephalon Solve Each Other's Problems

    May 4, 2011
    Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
  39. J&J Beats Analyst Expections, But Not Its Rivals

    April 25, 2011
    Tangible signs of sustained sales growth and consistent profit expansion are still absent at J&J.
  40. Quest Diagnostics Opens Its Wallet One More Time

    March 22, 2011
    Quest shows once again that it is willing to pay for what may become valuable testing technology.
  41. Risk With Little Reward At Johnson & Johnson

    January 27, 2011
    A number of Johnson & Johnson rivals trade at equally appealing valuations and have their acts together in terms of product ...
  42. Novartis Building Itself Into A One-Stop Shop

    January 26, 2011
    Novartis takes another step into molecular diagnostics.
  43. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  44. A Look At The Drug Makers Of 2010

    December 30, 2010
    Drug makers faced an uphill fight in 2010 and next year is looking to be just as tough.
  45. Has Ingenico Done VeriFone A Favor?

    December 23, 2010
    By rebuffing Danaher, Ingencio may be helping VeriFone.
  46. Novartis Brings Alcon Into The Fold

    December 16, 2010
    Novartis closes the deal for Alcon.
  47. Pfizer Ready To Create Value

    December 15, 2010
    Overall, Pfizer is a company with a cheap stock price, earnings power and numerous options to reward shareholders.
  48. Cooper: A Growing Play On Eye Care

    December 10, 2010
    Cooper is continuting to grow very well in a tough healthcare market, and shows signs of a shining future.
  49. Should Investors Take A Chance On Savient?

    October 26, 2010
    Savient's inability to sell itself puts almost everything about the company's value in flux.
  50. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  51. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma.
  52. Pharmaceutical Profits That Aren't For The Dogs

    March 15, 2010
    Merck and Sanofi-Aventis recently combined their animal health businesses, lending further evidence to the notion that this ...
  53. Fighting The Unstable European Union

    March 3, 2010
    Protection is the name of the game, and these options can help shield you from a volatile European Union.
  54. Novartis Looks For 20/20 Vision With Alcon

    January 11, 2010
    The Swiss drug maker hopes to take full ownership of Alcon later in the year. Find out what it'll mean for these two companies.
  55. Four Healthcare Stocks On Fire

    November 18, 2009
    Fourth healthcare stocks that have brushed aside any potential adversity that could arise from future legislation for the ...
  56. Four High-Flying Pharmaceutical Companies

    October 28, 2009
    A look at some of the best-performing stocks year to date - up anywhere from 400% to 2000%.
  57. Profit Using High And Low Turnover Funds

    September 24, 2009
    We look at the top five holdings for two of the best large growth funds over the last five years.
  58. Swine Flu Vaccine: Quantity Over Quality

    July 20, 2009
    The swine flu vaccine race appears to have multiple winners.
  59. Is Pfizer What The Doctor Ordered Or Bad Medicine?

    April 30, 2009
    Explore Pfizer, its earnings and its recent acquisition deal.
  60. Aging Population Feeds Global Healthcare Demand

    October 30, 2008
    Investing in foreign-based healthcare providers is as important as investing in healthcare providers with a global reach.
  61. Meet Teva, The Generic Giant

    May 15, 2008
    Success in generic drugs is all about high volume, low prices and global presence. Israel's Teva Pharmaceuticals has all ...
  62. Abbott Labs Finally Turns Potential Into Profit

    April 17, 2008
    Solid numbers for the last two quarters could change Abbott Labs's reputation as an overvalued stock.
  63. Green Funds For The Faint Of Heart

    March 24, 2008
    Learn about two funds that go green without going overboard. Both invest in well-known companies with strong growth potential.
  64. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
  65. A Look at Economic Moats - Part 2

    November 23, 2005
    In this piece we'll explore different types of economic moats.
Trading Center